Table 1 Clinical characteristics of patients
Variables | Total (n = 701) | 150 mg and 110 mg twice daily (n = 675) | 75 mg twice daily (n = 26) | P-value |
|---|---|---|---|---|
Age, years | 71.1 ± 10.9 | 70.8 ± 10.8 | 78.6 ± 10.0 | 0.004** |
Gender, female (%) | 244 (34.8%) | 231 (34.2%) | 13 (50.0%) | 0.098* |
Creatinine clearance: Ccr (mL/min) | 68.7 ± 25.3 | 69.4 ± 25.3 | 53.5 ± 20.9 | 0.003* |
History of bleeding | 79 (11.3%) | 74 (11.0%) | 5 (19.2%) | 0.191*** |
New users | 354 (50.5%) | 348 (51.6%) | 6 (23.1%) | 0.004*** |
Change from warfarin | 232 (33.1%) | 222 (32.9%) | 10 (38.5%) | 0.532*** |
C: Congestive heart failure | 138 (19.7%) | 128 (19.0%) | 10 (38.5%) | 0.002*** |
H: Hypertension | 426 (60.8%) | 406 (60.1%) | 20 (76.9%) | 0.041** |
A: Aged 75 or older | 294 (41.9%) | 278 (41.2%) | 16 (61.5%) | 0.021** |
D: Diabetes Mellitus | 140 (20.0%) | 133 (19.7%) | 7 (26.9%) | 0.117*** |
S: Stroke/TIA (2 points) | 185 (26.4%) | 177 (26.2%) | 8 (30.8%) | 0.327*** |
CHADS2 score | 1.95 ± 1.35 | 1.92 ± 1.33 | 2.54 ± 1.77 | 0.011* |
With antiplatelet agents | 129 (18.4%) | 125 (18.5%) | 4 (15.4%) | 0.686*** |